Small RNA-based therapy for pulmonary arterial hypertension: MiRNA-10 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 26/May/2015, 8.15 am

Small molecule-based Lifespan extension therapy: n-3 docosahexaenoic acid (DHA) may prolong mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 26/May/2015, 08.01 am
May 26, 2015
Regenerative therapy for DM: MiRNA-451 increases insulin-secreting cell mass and function via down regulation of its target genes, 26/May/2015, 8.30 am
May 26, 2015
Show all

Genome-2-Bio-Medicine Discovery center founder’s father’s (teacher) death anniversary day-26th  May

*********

On the eve of Genome-2-Bio-Medicine Discovery center founder’s father’s (teacher) death anniversary day, we wish to inform you that the ideas posted today (26/May/2015) will be available to the use of Scientists/Professors/Teachers/Physicians/Researchers for free. So, there will be no terms and conditions for the ideas posted today (26/May/2015). Each idea posted will be served first come, first served basis.Write to info@genomediscovery.org for more details. 

 

Dr L Boominathan PhD

President & CSO, GBMD.

*********************************************************************************************

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054] by Prof. Thistlethwaite PA, Li X and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small RNA-based therapy for pulmonary arterial hypertension: MiRNA-10 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3

Significance:  MiRNA-10, by decreasing the expression of its target gene, it may suppress the expression of Notch3. Thus, pharmacological formulations encompassing MiRNA-10 activators” may be used to treat pulmonary arterial hypertension

Undisclosed information: How MiRNA-10 decreases the expression of Notch3 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

To citeBoominathan, Small RNA-based therapy for pulmonary arterial hypertension: MiRNA-10 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 26/May/2015,  8.15 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.